This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Illumina Management Discusses Q2 2012 Results - Earnings Call Transcript

Adjusted research and development expenses for the quarter was $41 million or 14.7% of revenue compared to 14.9% of revenue in the first quarter and 14.1% of revenue in the second quarter of 2011. Adjusted SG&A expenses were $55 million or 19.4% of revenue compared to 18.9% of revenue in the first quarter and 19.1% of revenue in the second quarter of 2011.

Adjusted operating margins were a record 36.7% of revenue in the quarter compared to 35.8% of revenue in the second quarter of 2011 as we gain leverage from the improved gross margin performance.

Our non-GAAP tax rate for the quarter was 33.8% compared to 34.7% in the second quarter of last year. This quarter's tax rate was higher than the expected annualized rate as a result of the delay in the passage of the U.S. R&D tax credit. We anticipate the non-GAAP tax rate will continue to be approximately 34% until the R&D tax credit is passed and retroactively applied at some point this year.

Non-GAAP net income was $53 million for the quarter, and non-GAAP earnings per share was $0.40. This compares to non-GAAP net income and EPS of $52 million and $0.38, respectively, in the second quarter of 2011. We reported GAAP net income of $23 million or $0.18 per diluted share in the second quarter compared to $31 million or $0.22 per diluted share in the prior-year period. This includes an impairment charge this quarter of $21.4 million related to a technology asset acquired in 2010 and $6.7 million of ongoing unsolicited tender offer expenses.

Read the rest of this transcript for free on

4 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free


Chart of I:DJI
DOW 16,912.29 +122.10 0.73%
S&P 500 1,995.82 +15.90 0.80%
NASDAQ 4,791.1520 +42.7910 0.90%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs